ABSTRACT
Objective]To study Xin'an physician Wu Cheng asthenic diseases related theory of ideas in Bujuji, in order to more comprehensively understand asthenic diseases,to broaden the thinking, enhance the clinical curative effect. [Method]From the academic source of asthenic diseases , syndrome differentiation and treatment,prescription medication,clinical academic value, make research on Wu's thought about asthenic diseases treatment. [Result]Wu Cheng combined with their own perception and experience of clinical evidence, first put forward“external damage caused by asthenic diseases”;Aiming at the asthenic diseases of the treatment,Wu Cheng creatively put forward“support solution method”, “supplementary care method”, “treatment of spleen yin”;Wu Cheng's life was exploring the asthenic diseases,the theory of asthenic diseases had good clinical academic value,not only for the development of the cause of disease theory,but also enriching the theory of health prevention.[Conclusion]Wu Cheng Bujuji rich in content and its syndrome differentiation of asthenic diseases, with much experience, as today, treatment based on the thought of clinical asthenic diseases treatment still has important guiding significance.
ABSTRACT
The patent eustachian tubes (PET) of five patients with a chief complaint of aural fullness were successfully treated with kigikenchuto. A Kampo extract preparation of ogikenchuto and tokikenchuto (daily dose of 9 and 7.5 g, respectively) was applied as a representative prescription for kigikenchuto. The five patients had also been diagnosed with definitive PET on otological examination. Case 1 was a 73-year-old male suffering from aural fullness and autophonia after a common cold. These ear symptoms improved on lying down and resting. He had a history of admission for cerebral hemorrhage with hypertension and weight loss. Bilateral stiffness of the abdominal rectus muscle and an intolerable tickling sensation were noted. After taking kigikenchuto for two weeks, his symptoms improved. An additional study of four patients treated with kigikenchuto, including Case 2, a 75-year-old female, Case 3, a 33-year-old female, Case 4, a 78-year-old female, and Case 5, a 21-year-old male, showed effective cures. Kigikenchuto is a <i>qi</i>-blood supplementing derivative of shokenchuto, a minor center-reinforcing Kampo medicine for asthenic disease. Based on these results, we suggested that kigikenchuto serves as a useful formulation to treat PET. Life guidance to promote health is also essential for cure.